Zacks Small Cap Weighs in on Rani Therapeutics Holdings, Inc.’s FY2026 Earnings (NASDAQ:RANI)

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) – Zacks Small Cap issued their FY2026 earnings per share (EPS) estimates for shares of Rani Therapeutics in a research note issued to investors on Thursday, May 9th. Zacks Small Cap analyst J. Vandermosten forecasts that the company will earn ($0.75) per share for the year. The consensus estimate for Rani Therapeutics’ current full-year earnings is ($1.01) per share.

Several other brokerages also recently weighed in on RANI. BTIG Research increased their target price on shares of Rani Therapeutics from $7.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Rani Therapeutics in a research note on Tuesday, February 6th. Canaccord Genuity Group cut their price target on Rani Therapeutics from $21.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, March 27th. Finally, HC Wainwright lifted their price objective on shares of Rani Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Rani Therapeutics has an average rating of “Buy” and a consensus price target of $12.20.

Rani Therapeutics Stock Performance

Shares of NASDAQ:RANI opened at $5.78 on Monday. The company has a current ratio of 3.09, a quick ratio of 3.09 and a debt-to-equity ratio of 1.43. Rani Therapeutics has a 1-year low of $1.82 and a 1-year high of $8.75. The firm has a fifty day moving average price of $4.93 and a 200 day moving average price of $3.66.

Rani Therapeutics (NASDAQ:RANI) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.04.

Institutional Investors Weigh In On Rani Therapeutics

An institutional investor recently raised its position in Rani Therapeutics stock. Vanguard Group Inc. increased its stake in shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) by 2.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 685,303 shares of the company’s stock after buying an additional 16,956 shares during the period. Vanguard Group Inc. owned about 1.37% of Rani Therapeutics worth $2,131,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 30.19% of the company’s stock.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.